4 June 2014
Implantable cardioverter-defibrillators (ICDs) improve survival in patients with less severe heart failure, suggests new research published in the latest issue of JAMA.
Although ICDs are the best treatment currently available to prevent sudden cardiac death in patients with heart failure, some uncertainties still surround using them as a preventative measure.
To conduct the study, the research team compared to survival rates of those with the condition who’d had the implantable device fitted to those who had not.
At one year, 24.5 per cent of ICD patients died compared to 24.9 per cent of the comparison group. At three years the differences become more noticeable, with 51.4 per cent of those with the device dying compared to 55 per cent of non-ICD patients.
According to the authors of the report, although the difference - 3.6 per cent - in risk at three years was not massive, it was significant and close in magnitude to what other studies of preventative ICDs had discovered.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.